Umbilical Cord Bilirubin Predicts Neonatal Jaundice
By LabMedica International staff writers Posted on 17 Oct 2017 |
Image: The GEM 4000 whole blood analyzer (Photo courtesy of Werfen UK).
Hyperbilirubinemia is one of the commonest causes of admission to hospital in the neonatal period amongst term babies in all settings. Prevention of serious complications depends on effective early treatment, but clinically significant jaundice may not develop until one or more days after delivery.
Identification of biomarkers that could be measured within a few hours following birth, which robustly predict incident jaundice, would represent a significant advance. Estimation of umbilical cord blood bilirubin (UCB) at delivery is practicable, cheap and non-invasive. It could be easily integrated with the current trend towards routine umbilical cord blood biochemical evaluation practiced in many centers.
Neonatal specialists at Homerton University Hospital (London, UK) carried out a retrospective analysis of hospital biochemistry records identified term deliveries with recorded arterial UCB (aUCB). Infant medical records were reviewed to identify those who developed neonatal hyperbilirubinemia requiring treatment according to UK NICE guidelines, with/without a positive direct antiglobulin test (DAT). Over the 9-month period, there were 4,069 inborn deliveries, on who umbilical cord blood analysis had been performed on 2,128 (52.2%). The neonatal unit is equipped with a GEM 4000 whole blood analyzer, which automatically provides total bilirubin estimation on samples.
Of 1,411 term deliveries with a clearly recorded aUCB, 30 infants developed clinically significant jaundice (2.7%), of whom eight were DAT + ve (0.6%) mostly due to ABO incompatibility. aUCB strongly predicted the development of DAT + ve jaundice, as well as all-cause jaundice. However, this effect was critically dependent on maternal blood group. Amongst infants at risk of ABO incompatibility (maternal blood groups O+ve/O-ve, 39.7%) the predictive value of aUCB for all cause jaundice was strengthened. Amongst those not at risk (defined maternal blood group not O+ve/O-ve, 51.0%) it disappeared completely. A cutoff of 35 μmol/L for mothers with blood group O+ve/O-ve increased the pre-test probability for all-cause jaundice of 4% to a post-test probability of 30%.
The authors concluded that for infants of mothers with blood group O, aUCB predicts development of neonatal jaundice. There was no evident utility for infants of mothers with other blood groups. Estimation of aUCB should be considered as a strategy for early identification of those at risk of neonatal hemolytic jaundice. The study was published on September 20, 2017, in the journal BMC Pediatrics.
Related Links:
Homerton University Hospital
Identification of biomarkers that could be measured within a few hours following birth, which robustly predict incident jaundice, would represent a significant advance. Estimation of umbilical cord blood bilirubin (UCB) at delivery is practicable, cheap and non-invasive. It could be easily integrated with the current trend towards routine umbilical cord blood biochemical evaluation practiced in many centers.
Neonatal specialists at Homerton University Hospital (London, UK) carried out a retrospective analysis of hospital biochemistry records identified term deliveries with recorded arterial UCB (aUCB). Infant medical records were reviewed to identify those who developed neonatal hyperbilirubinemia requiring treatment according to UK NICE guidelines, with/without a positive direct antiglobulin test (DAT). Over the 9-month period, there were 4,069 inborn deliveries, on who umbilical cord blood analysis had been performed on 2,128 (52.2%). The neonatal unit is equipped with a GEM 4000 whole blood analyzer, which automatically provides total bilirubin estimation on samples.
Of 1,411 term deliveries with a clearly recorded aUCB, 30 infants developed clinically significant jaundice (2.7%), of whom eight were DAT + ve (0.6%) mostly due to ABO incompatibility. aUCB strongly predicted the development of DAT + ve jaundice, as well as all-cause jaundice. However, this effect was critically dependent on maternal blood group. Amongst infants at risk of ABO incompatibility (maternal blood groups O+ve/O-ve, 39.7%) the predictive value of aUCB for all cause jaundice was strengthened. Amongst those not at risk (defined maternal blood group not O+ve/O-ve, 51.0%) it disappeared completely. A cutoff of 35 μmol/L for mothers with blood group O+ve/O-ve increased the pre-test probability for all-cause jaundice of 4% to a post-test probability of 30%.
The authors concluded that for infants of mothers with blood group O, aUCB predicts development of neonatal jaundice. There was no evident utility for infants of mothers with other blood groups. Estimation of aUCB should be considered as a strategy for early identification of those at risk of neonatal hemolytic jaundice. The study was published on September 20, 2017, in the journal BMC Pediatrics.
Related Links:
Homerton University Hospital
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines